Padcev 20mg Injection contains the active substance Enfortumab vedotin. It is an antineoplastic drug that belongs to the class of antibody-drug conjugates (ADCs). Padcev 20mg Injection is used to treat adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.

Padcev 20mg Injection works by targeting a protein called Nectin-4, which is highly expressed in urothelial cancer cells. The drug delivers a cytotoxic agent known as monomethyl auristatin E (MMAE) directly to the cancer cells. Once inside the cells, MMAE disrupts the microtubule network, leading to cell cycle arrest and cell death. This targeted mechanism helps to destroy cancer cells while minimizing damage to healthy tissues.

Do not give Padcev 20mg Injection to children or adolescents under the age of 18.

Do not use Padcev 20mg Injection if you are allergic to Enfortumab vedotin or any other ingredients of this medicine. Before starting treatment, inform your doctor if you have a history of kidney problems, heart conditions, or eye disorders or if you’ve experienced lung inflammation. Report any symptoms such as difficulty breathing with cough or fever, severe skin peeling, persistent fever, easy bruising or bleeding, unusual tiredness, pale skin, or signs of infection to your healthcare provider promptly.

Locally advanced or metastatic urothelial cancer in adult patients who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.

Padcev Injection works by targeting Nectin-4 on cancer cells and delivering monomethyl auristatin E (MMAE), a cytotoxic agent. Once inside the cancer cells, MMAE interferes with the microtubule network, causing cell cycle arrest and triggering cell death (apoptosis). This targeted mechanism enables the selective destruction of cancer cells while minimizing harm to healthy tissues.

Treatment with Padcev Injection should be initiated and supervised by a physician experienced in anti-cancer therapies in a hospital setting, with administration in a healthcare facility equipped to manage potential infusion-related reactions. Padcev 20mg Injection is given as an intravenous (IV) infusion under the supervision of a qualified healthcare professional, requiring good venous access before starting treatment. This medication must not be self-administered.

Fatigue

Nausea

Decreased appetite

Diarrhea

Rash

Hair loss (alopecia)

Altered taste (dyspepsia)

Dry eyes

Serious side effects of Padcev 20mg Injection are:

Severe Peripheral Neuropathy: May require dose adjustment or discontinuation of treatment.

Serious Skin Reactions: Including conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis; treatment should be stopped immediately if these occur.

Hyperglycemia: Can result in ketoacidosis or hyperosmolar hyperglycemic state; requires careful monitoring and management.

It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Padcev 20mg Injection, potentially affecting their effectiveness or causing side effects.

Keep out of reach of children and pets.

Store in the original container.

Store Padcev Injection in a refrigerator at a temperature of 2ºC to 8ºC.

Do not freeze.

Patients should immediately report any new or worsening symptoms, especially those related to nerve function, skin reactions, or blood sugar levels. Regular communication with healthcare providers is essential for the prompt management of side effects. Adhering to scheduled appointments and monitoring protocols is vital for the safe and effective use of treatment. Additionally, patients should follow their doctor’s advice regarding any necessary adjustments to their therapy.